Compare Procter & Gamble Co (PG) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Procter & Gamble Co vs Zoetis Inc — how do they compare? Procter & Gamble Co trades at $150.46 (market cap $343.34B), while Zoetis Inc trades at $73.06 (market cap $29.57B). The key difference: Procter & Gamble Co is far larger — about 11.6× Zoetis Inc's market cap, and Zoetis Inc pays the higher dividend (2.96%). Which is the better fit depends on your goals — on Pluang, investors hold Procter & Gamble Co for 131 Days and Zoetis Inc for 70 Days on average.
| PG | ZTS | |
|---|---|---|
Market Cap | $343.34B | $29.57B |
Volume | 8,662,344 | 4,128,093 |
Sector | Consumer Staples | Health |
52-Week High | $167.18 | $147.53 |
52-Week Low | $138.10 | $69.09 |
Typical Hold Time | 131 Days | 70 Days |
Enterprise Value | $369.18B | $37.13B |
Dividend Yield | 2.95% | 2.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Procter & Gamble (PG) trades at $150.59, up 1.47% today, with a bullish technical signal from moving averages and a consensus analyst price target of $160.13. The company reported revenue of $84.28 billion in 2025, with net income of $15.97 billion and strong profitability margins. Recent earnings have consistently beaten expectations, and the stock offers a dividend yield with a history of increases.
PG presents a stable investment with consistent earnings and dividend growth, supported by a robust balance sheet. Risks include premium valuation multiples and modest revenue growth outlook. Analyst sentiment is predominantly positive, with 53% buy ratings, but investors should monitor competitive pressures and economic sensitivity.
Zoetis (ZTS) trades at $73.08, up 2.47% on the day, but remains in a bearish technical trend with support near $70. Fundamentally, the company reported strong 2025 results with $9.47B revenue, $2.67B net income, and robust margins, though recent quarters show mixed earnings performance. Analyst consensus is a Buy with a $87.33 price target, but sentiment is cautious due to U.S. pet care weakness and competitive pressures.
The stock offers value with a P/E of 11.67 and a 3% dividend yield, but near-term headwinds include declining U.S. companion animal sales and margin compression. Long-term growth prospects remain intact given industry leadership and international resilience, making it a contrarian opportunity for patient investors despite technical and competitive risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Procter & Gamble Co
The Procter & Gamble Company manufactures and markets consumer products in countries throughout the world. The Company provides products in the laundry and cleaning, paper, beauty care, food and beverage, and health care segments. Procter & Gamble products are sold primarily through mass merchandisers, grocery stores, membership club stores, drug stores, and neighborhood stores.
Read more on PG →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
